Roundworms of the genus Ascaris are common parasites of the human gastrointestinal tract. A battery of selective inhibitors protects them from host enzymes and the immune system. Here, a metallocarboxypeptidase (MCP) inhibitor, ACI, was identified in protein extracts from Ascaris by intensity-fading MALDI-TOF mass spectrometry. The 67-residue amino acid sequence of ACI showed no significant homology with any known protein. Heterologous overexpression and purification of ACI rendered a functional molecule with nanomolar equilibrium dissociation constants against MCPs, which denoted a preference for digestive and mast cell A/B-type MCPs. Western blotting and immunohistochemistry located ACI in the body wall, intestine, female reproductive tract, and fertilized eggs of Ascaris, in accordance with its target specificity. The crystal structure of the complex of ACI with human carboxypeptidase A1, one of its potential targets in vivo, revealed a protein with a fold consisting of two tandem homologous domains, each containing a ␤-ribbon and two disulfide bonds. These domains are connected by an ␣-helical segment and a fifth disulfide bond. Binding and inhibition are exerted by the C-terminal tail, which enters the funnel-like active-site cavity of the enzyme and approaches the catalytic zinc ion. The findings reported provide a basis for the biological function of ACI, which may be essential for parasitic survival during infection.
M
ore than a quarter of the human population is affected by soil-transmitted helminthes, which impair nutrition and the immune response toward widespread pandemics such as AIDS and tuberculosis (1, 2) . The roundworm Ascaris lumbricoides is the most common human parasite of the gastrointestinal tract. It causes ascariasis (3) , which has a worldwide distribution with highest prevalence in tropical and subtropical regions and in areas with inadequate sanitation. Ascariasis is triggered by the ingestion of parasite eggs. These evolve to larvae that migrate through different tissues and return to the small intestine, where they mature to adult male and female worms. At this stage, females deposit thousands of eggs daily, which are secreted with the feces, thus contributing to soil contamination and spreading of the infection [for details, see supporting information (SI) Fig.  S1 ]. During its life cycle, Ascaris threatens human health with nonspecific abdominal symptoms, intestinal obstruction and perforation, biliary colic, gallstone formation, liver abscesses, pancreatitis, and pulmonary eosinophilia (4, 5) . A nearly identical nematode species, Ascaris suum, is found in the pig. It has a tremendous impact on livestock farming and can also infect primates and humans, giving rise to a similar disease pattern to A. lumbricoides (6) (7) (8) .
As part of the parasite defense strategy, Ascaris roundworms secrete a series of inhibitors to target digestive and immunerelated host proteases, among others pepsin, trypsin, chymotrypsin/elastase, cathepsins, and metallocarboxypeptidases (MCPs) (9) (10) (11) (12) (13) (14) (15) (16) . MCPs are zinc-containing exoproteases that catalyze the hydrolysis of C-terminal amino acids from proteins and peptides. They perform a large variety of physiologically relevant functions in organisms of different phyla (17) . These enzymes have been grouped into the funnelin tribe of proteases and are subdivided into A/B-and N/E-type MCPs (18) . Human A/B-type funnelins include the digestive enzymes CPA1, CPA2, and CPB1, and mast cell CPA3, which is related to inflammatory processes (19, 20) . The biological action of MCPs is specifically modulated through protein inhibitors. To date, seven such MCP inhibitors have been described from potato and tomato (PCI and MCPI; 38 and 39 residues, respectively) (21, 22) , medical leech Hirudo medicinalis (LCI; 66 residues) (23), the ticks Rhipicephalus bursa and Haemaphysalis longicornis (TCI and HlTCI; 75 and 77 residues, respectively) (24, 25) , rat and human latexin (alias ECI; 222 and 223 residues, respectively) (26, 27) , and the intestinal parasites A. lumbricoides and A. suum (ACI) (12, 13) . Although the former inhibitors have been studied extensively in terms of activity and structure, ACI has hitherto only been studied for its amino acid sequence. We present here its cloning, heterologous expression, purification, and three-dimensional structure in complex with a MCP, unveiling its mechanism of inhibition. We also report its target specificity and in vivo localization in Ascaris worms, which lead to a deeper understanding of the life-threatening disease ascariasis and may pave the way for drug and vaccine development.
Results and Discussion
Identification, Sequencing, and Cloning of ACI from Ascaris. Initial recombinant overexpression trials of ACI on the basis of the reported amino acid sequence (12) produced only minute yields and two distinct forms (termed A and B; see Fig. S2 ) of identical molecular mass (7,502.5 Da) and 8 cysteine residues forming four disulfide bonds. Of these two, only form B inhibited bovine carboxypeptidase A1 (bCPA1), albeit weakly (K i ϭ 5.9 Ϯ 0.2 M) compared with other reported MCP inhibitors (17) . We thus attempted to analyze ACI directly from a crude homogenate of Ascaris worms. After assessing the presence of inhibitory activity against bCPA1 (see SI Materials and Methods), the extract was subjected to intensity fading MALDI-TOF mass spectrometry (28) . This procedure rendered a molecular mass of 7,724.8 Da for the Ascaris MCPI ( Fig. 1 A and B) , which did not match that of the reported sequence (12) . The inhibitor was purified by using a combination of affinity chromatography and reversed-phase HPLC. Its 30 N-terminal residues matched the sequence reported (12) . However, the protein had 10 rather than 8 cysteine residues, and subsequent analysis of peptides obtained by digestion with endoproteinase Lys-C revealed that the C terminus (-GCCWDLL 67 ) had been erroneously determined (-LPWGL 65 ) (12) . Therefore, the cDNA of ACI was cloned (Fig.  1C) , and it was found to consist of 467 nucleotides, with a deduced protein sequence of 87 residues. The first 20 residues correspond to a signal peptide that precedes the aspartate residue found at the N terminus of the purified inhibitor. The calculated molecular mass of the deduced mature protein was consistent with that of natural ACI determined by MALDI-TOF mass spectrometry, with five disulfide bonds. Sequence similarity searches revealed no homology with any other reported sequence with the exception of the C terminus, which showed certain resemblance to the C termini of other reported MCPIs (see below and Fig. 3D ).
Heterologous Expression and Purification of ACI. Recombinant ACI was overexpressed in Escherichia coli as a fusion protein (Fig.  S3) , whose cleavage left a glycine residue at the N terminus of the inhibitor protein (molecular mass of 7,781.8 Da). A final reversed-phase HPLC step rendered a unique peak with a retention time equivalent to that of natural ACI. The typical yield was Ϸ10 mg of pure recombinant ACI per L of cell culture.
Conformational Stability and Activity of ACI. Circular dichroism and NMR spectroscopy experiments showed that the conformations of natural and recombinant ACI were indistinguishable. Both molecules maintained a well-folded conformation in a wide range of chaotropic reagents and temperature and only became denatured by the simultaneous presence of denaturing and reducing agents (Figs. S4 and S5 ). This high stability may be attributed to the five disulfide bonds, which strongly constrain the ACI structure, as reported for PCI, LCI, and TCI (29) (30) (31) . Equilibrium dissociation constants for the complexes of natural ACI and recombinant ACI with a selection of MCPs were indistinguishable (data not shown). This agreement revealed that ACI is a tight binding, competitive inhibitor of A/B-type but not N/E-type funnelins, with K i values in the nanomolar range (Table 1) . Within this potency, the inhibitor showed a distinct specificity for digestive enzymes (CPA1, CPA2, and CPB1) and mast cell CPA3 over CPA4 and plasma CPB2 (also called TAFIa), which displayed significantly higher (10-20 times) K i values.
Immunolocalization of ACI in Ascaris. Specific antibodies raised against recombinant ACI were used to detect the protein in extracts from adult male and female Ascaris tissues by Western blot analysis. The inhibitor was found in the intestine and body wall of both male and female worms and in the ovary and uterus Ten independent experiments were conducted to draw the plot. The molecular mass of the inhibitor identified by intensity fading MALDI-TOF mass spectrometry is labeled with an asterisk. (C) Nucleotide and deduced amino acid sequence of ACI. The full-length cDNA sequence was assembled from two overlapping clones obtained by 5Ј-and 3Ј-RACE techniques (nucleotides 1-315 and 179 -467, respectively). It contains a 49-nucleotide 5Ј-untranslated sequence, an ORF of 264 nucleotides, and a 154-nucleotide 3Ј-untranslated region. A canonical polyadenylation signal, AATAAA (underlined), is detected 12 nucleotides upstream from the poly(A) ϩ tail. The amino acid sequence of mature ACI is printed in bold. Two isoforms (boxed) are found at the triplets codifying for residues at positions 32 and 37, caa/gaa (glutamine/glutamate) and gaa/caa (glutamate/glutamine), respectively. of female worms (Fig. S6) . Immunohistochemistry assays confirmed these results. Antibodies strongly recognized the inhibitor in the intestine and hypodermis (body wall) of male and female worms (Fig. 2) . In the body wall the signal was especially strong around the lateral chords, which contain the excretory canals. In females, the immunostaining was weaker in the uterus, ovary, and oviduct, whereas it was strong in the fertilized eggs. No labeling was detected in the male reproductive system (i.e., testis, vas deferens, and seminal vesicle).
Structure of the ACI in Complex with Human CPA1. The crystal structure analysis of human CPA1 (hCPA1) in its complex with recombinant ACI (Fig. 3A) reveals that the protease conforms to the classic ␣/␤-hydrolase fold of A/B-and N/E-type zincdependent MCPs of the funnelin tribe of proteases (for a detailed description of the hCPA1 structure, see SI Materials and Methods) (17, 18, 32) . ACI consists of structurally similar tandem modules, an N-terminal domain (NTD; Val-3I-Ser-26I; inhibitor residues carry an I suffix) and a C-terminal domain (CTD; Thr-40I-Leu-67I), which are linked by a connecting segment (CS; Thr-27I-Phe-39I) ( Fig. 3 A and B) . Each domain comprises a short N-terminal segment in extended conformation followed by a 90°turn that leads to a double, intertwined 1,4-turn.
Thereafter, the chain folds back to enter a C-terminal ␤-ribbon (Fig. 3A and Fig. S7A ). Intradomain stabilization is provided by two internal disulfide bonds per domain. The CS includes an ␣-helix (Ile-28I-His-38I) that is linked to the second ␤-ribbon strand of the CTD via a fifth disulfide bond (Cys-34I-Cys-62I). The two domains interact with each other through the N terminus and the tip plus the second strand of the ␤-ribbon of the NTD, the CS helix, and the N-terminal segment in extended conformation and the double 1,4-turn of the CTD (Fig. 3A and  Fig. S7A ). The domain architecture of ACI resembles that of latexin, in which two tandem cystatin-like modules are linked by a helical segment (33) . However, there is no structural similarity with latexin beyond this coincidence in the modular arrangement, and no significant structural homology was found with any structure reported. We conclude that ACI conforms to a new fold and that this inhibitor may have arisen by gene duplication.
Structural Determinants of hCPA1 Inhibition Through ACI. ACI inhibits hCPA1 by blocking access to the active-site cleft through an interface of 690 Å 2 by forming 35 close contacts, including 12 hydrogen bonds and 6 hydrophobic interactions (see Table S1 ). Complex formation involves the C-terminal tail (Trp-64I-Leu-67I) and the tip (Asn-59I-Lys-60I) and the center (Ile-57I) of the N-terminal ␤-ribbon strand of the CTD and the end of the CS (Glu-37I-Phe-39I) of ACI, i.e., the NTD is not involved. Intervening segments of hCPA1 include the funnel-rim loop connecting strand ␤3 with helix ␣2, L␤3␣2, two regions of L␣4␣5, as well as L␤5␤6, L␣7␣8, and L␤8␣9. The main determinant of inhibition is the C-terminal stretch of ACI, which extends and penetrates the active-site cleft ( Fig. 3A and Fig. S7B ). This extended conformation is held together by the second disulfide bond of the CTD and a -stacking interaction of Trp-64I with Asn-59I N␦2 (Fig. S7B) . ACI occupies the active-site cleft subsites S 3 , S 2 , and S 1 , and the C-terminal carboxylate oxygen atoms coordinate the catalytic zinc ion of the mature protease moiety in a slightly asymmetric bidentate manner (2.06 Å and 2.41 Å away, respectively). On the primed side of the cleft, an acetate ion lies next to the zinc, partially occupying the S 1Ј specificity pocket and mimicking the C terminus of a substrate. The acetate establishes a double salt bridge with Arg-145 N1 (2.77 Å) and N2 (2.94 Å) of the protease. One of its carboxylate oxygens binds Tyr-248 (2.62 Å) and the other hydrogen bonds Asn-144 N␦2 (2.86 Å).
The way in which ACI inhibits hCPA1 resembles the action of PCI, LCI, and TCI but not latexin (33) (34) (35) (36) (37) . Although the latter completely shields the active site of its target MCP in a nonspecific manner by contacting funnel rim elements, the other three inhibitors interact with these elements, but their C-terminal tails protrude into the active-site cleft in a substrate-like manner, as found for ACI ( Fig. 3 C and D) . Superposition of the C-terminal residues of the four inhibitors, which come from evolutionary distant species, reveals moderate sequence similarity. However, while the C-terminal residue is cleaved off in PCI, LCI, and TCI upon complex formation, it remains unaltered in ACI. This happens because the last residue of ACI matches the penultimate residues of PCI, LCI, and TCI (Fig. 3D ).
Conclusions
Here, we have comprehensively analyzed the inhibitor ACI in the intestinal parasite Ascaris, the first to target metallopeptidases. Its preferential inhibition of MCPs found in the intestine and mast cells of the intestinal mucosa of the host would explain that Ascaris can survive in a hostile environment for many years by evading or dampening host responses that might otherwise kill it or trigger its expulsion. These data are consistent with the specific localization of ACI in the intestine and body wall of male and female Ascaris worms and in fertilized eggs. Such localization is compatible with the protection of adult worms and eggs in the host intestine and of the larvae during migration.
Structural analysis revealed that ACI consists of two linked homologous tandem domains. Inhibition of hCPA1 involves only the CTD and the preceding CS but not the NTD. This domain may target other digestive enzymes present in the host gut, as reported, for example, for the bifunctional ␣-amylase/trypsin inhibitor from the Indian finger millet Ragi (38) . and Table S2 . Briefly, the ACI inhibitor was identified in an extract of Ascaris by intensity fading MALDI-TOF mass spectrometry as described in ref. 28 . The inhibitor was subsequently isolated by CPA-Sepharose affinity chromatography and reversed-phase HPLC and sequenced by automated Edman degradation. The full-length ACI cDNA was cloned by RT-PCR and 5Ј/3Ј-RACE techniques as described in ref. 24 . Recombinant ACI was overexpressed in E. coli Origami cells by using the pET-32a-derived vector, pET-32a-ACI, which contains a thioredoxin-hexahistidine fusion followed by a tobacco-etch virus (TEV) protease cleavage site. The fusion protein was purified by Ni 2ϩ affinity chromatography and subsequently digested with TEV protease. The inhibitor was purified to homogeneity by RP-HPLC. Natural and recombinant ACI were analyzed by CD and NMR spectrometry under native and denaturing conditions. Their inhibitory activity was tested by spectophotometric assays with selected chromogenic substrates as described in ref. 24 . Natural ACI was detected in adult male and female Ascaris dissected in different tissues or cut in slides by Western blotting or immunohistochemistry by using standard protocols. The ACI-hCPA1 complex was prepared by incubating equimolar quantities of enzyme and inhibitor. Crystals were obtained by using the sitting-drop vapor diffusion method. The structure was solved by Patterson search by using the coordinates of unbound hCPA1 as a searching model.
Materials and Methods

A detailed description of procedures is provided in SI Materials and Methods
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Heterologous Expression and Purification of ACI with the Reported
Sequence. ACI as cloned into the pBAT-4 vector was expressed as described for tick carboxypeptidase inhibitor (TCI) (6) . For expression with the pET-32a vector, which attaches an Nterminal thioredoxin-His 6 fusion and an enterokinase cleavage site, E. coli Origami2 (DE3) cells (Novagen) were transformed with the plasmid and grown overnight at 30°C in Luria-Bertani (LB) medium with 100 g/mL carbenicillin and 13 g/mL tetracycline. The medium was then diluted 1:10 (vol/vol) in fresh LB containing the same antibiotics. Cells were grown at 37°C and induced to express the protein at an OD 550 of 0.8 with 0.5 mM IPTG (final concentration). The cells were incubated overnight at 18°C and then harvested by centrifugation. The pellet was washed three times in 20 mM Tris⅐HCl, 150 mM NaCl (pH 7.5) and resuspended in 50 mM Tris⅐HCl, 50 mM NaCl, 10 mM imidazole (pH 8.0). Cells were lysed by sonication in an ice bath, and the cell debris was subsequently removed by centrifugation at 35,000 ϫ g for 30 min at 4°C. The supernatant was loaded onto a 5-mL HiTrap HP column (GE Healthcare) equilibrated with 50 mM Tris⅐HCl, 50 mM NaCl, 10 mM imidazole (pH 8.0). The column was washed in the same buffer further containing 100 mM imidazole at a flow rate of 1 mL/min, and the bound proteins were eluted with 450 mM imidazole. The eluted fractions were pooled, checked by 15% SDS/PAGE stained with Coomassie blue, desalted with a HiPrep 26/10 desalting column (GE Healthcare), and digested with 0.25 unit of enterokinase (Invitrogen) per mg of recombinant protein. The digestion products were analyzed by MALDI-TOF mass spectrometry (MS), and the recombinant ACI protein with the reported sequence was cleaved from the thioredoxin fusion protein and purified by reversed-phase high performance liquid chromatography (RP-HPLC) in a Waters Alliance apparatus as follows. The protein was loaded onto a 4.6-mm protein C4 column (Vydac Grace) by using a linear gradient from 10 to 50% acetonitrile with 0.1% trifluoroacetic acid at a flow rate of 0.75 mL/min for 50 min. ACI, with the reported sequence as cloned into the pBAT-4-OmpA vector, was expressed and purified as described in detail for potato carboxypeptidase inhibitor (PCI) and TCI (7, 8) . ACI protein with the reported sequence cloned into the pPICZ␣ vector was expressed in the P. pastoris strain KM71H as described above for different CPs. In all cases, protein expression was monitored by MALDI-TOF MS (see below for details).
Intensity-Fading MALDI-TOF MS Assay. Ascaris worms (10 specimens) maintained on ice were washed three times in PBS and homogenized by using a Polytron and 50 mM Tris⅐HCl, 150 mM NaCl (pH 7.5) as buffer. The insoluble fraction of the homogenate was removed by centrifugation at 35,000 ϫ g for 30 min at 4°C. The soluble fraction was loaded onto a Sep-Pak light C18 Cartridge (Waters) and washed in water, and the bound proteins were eluted with 60% acetonitrile and subsequently lyophilized. The protein extract was resuspended in 0.5 mL of 20 mM Tris⅐HCl (pH 7.5), analyzed by MALDI-TOF MS, and then treated as detailed below. bCPA1 was coupled to cyanide bromide-activated Sepharose 4B following the manufacturer's guidelines (GE Healthcare) to give CPA-Sepharose. For the intensity-fading MS assays (9), 2-3 L of the Ascaris extract was mixed with 2-3 L of CPA-Sepharose on a small strip of parafilm and incubated for 5 min at room temperature. Then, 0.5 L from the top of the drop was recovered and analyzed by MALDI-TOF MS. The CPA-Sepharose was washed twice with 5 L of 10 mM Tris⅐HCl (pH 7.5) and with 5 L of 50 mM sodium phosphate (pH 11.0). Two to three microliters of 100% formic acid was mixed with the CPA-Sepharose and incubated for 5 min to release the bound carboxypeptidase inhibitor; 0.5 L from the top of the drop was removed for the final MALDI-TOF MS analysis. All samples were mixed with a matrix solution (1:1, vol/vol) of 10 mg/mL 2,6-dihydroxyacetophenone (Sigma) dissolved in 30% acetonitrile containing 20 mM dibasic ammonium citrate (pH 5.5); 0.5 L of the mixture was spotted onto the MALDI-TOF plate by using the dried-droplet method. Mass spectra were acquired in an Ultraf lex mass spectrometer (Bruker) equipped with a 337-nm laser in linear-mode geometry under 20 kV and Ϸ300 laser shots. A mixture of proteins from Bruker (protein calibration standard I; mass range 3,000-25,000 Da) was used as a standard.
Purification of Natural ACI. Approximately 1 kg of Ascaris worms was homogenized in 50 mM Tris⅐HCl, 150 mM NaCl (pH 7.5), by using a Polytron and centrifuged at 35,000 ϫ g for 30 min at 4°C. The soluble fraction of the extract was loaded onto a 20-mL CPA-Sepharose affinity column prepared as described above. The column was washed with 50 mM Tris⅐HCl (pH 9.0) followed by 50 mM Tris⅐HCl (pH 10.0) and eluted with 20 mM sodium phosphate (pH 12.0). The proteins eluted at this pH were lyophilized, and ACI was finally purified by RP-HPLC by using the conditions detailed above. All of the purification steps were monitored by MALDI-TOF MS.
Carboxymethylation and Amino Acid Sequencing. To determine the number of cysteine residues, the natural ACI inhibitor was reduced with 50 mM DTT in 100 mM Tris⅐HCl (pH 8.5) for 3 h and subsequently incubated with 200 mM 4-vinylpyridine for 45 min at room temperature in the dark. The solution was diluted 10 times with deionized water and analyzed by MALDI-TOF MS by using 2,6-dihydroxyacetophenone as matrix solution. Each free cysteine residue incorporates one S-pyridylethyl group with the consequent increase in mass of 105 Da. For the sequence analyses, ACI was reduced and carboxymethylated as described, freed from reagents by RP-HPLC, and either directly analyzed by automated Edman degradation in an Applied Biosystems model Procise 492 protein sequencer or digested with endoproteinase Lys-C (Roche Applied Science) in 20 mM Tris⅐HCl (pH 8.0) for 3 h at 37°C by using an enzyme:substrate ratio of 1:100 (wt/wt). The resulting peptides were isolated by RP-HPLC on a Vydac C18 column with a linear gradient of 10-60% acetonitrile with 0.1% trifluoroacetic acid at 0.75 mL/min for 50 min and lyophilized. Peptide sequences were obtained by automated Edman degradation.
Molecular Cloning of Full-Length ACI cDNA. Total RNA was extracted from frozen Ascaris worms by using the nucleospin RNA L kit (Macherey Nagel) following the manufacturer's instructions. The first strand of the Ascaris cDNA was synthesized by using the adaptor oligonucleotide R 0 R 1 -dT (R 0 , 5Ј-CCGGAAT-TCACTGCAG-3Ј; R 1 , 5Ј-GGTACCCAATACGACTCAC-TATAGGGC-3Ј) and avian myeloblastosis virus reverse transcriptase (Roche Applied Science). To clone ACI cDNA, two degenerate oligonucleotides were designed from the amino acid sequence published for ACI (4): N1, GAYACIGAYTGYA-CIAAYGGIGARAARTG (corresponding to residues Asp-9-Cys-18) and N2, GGIGARAARTGYGTICARAARAA-YAARAT (residues Gly-15-Ile-24), with Y ϭ C or T, R ϭ A or G, and I ϭ inosine. The 3Ј-end fragment of ACI cDNA was obtained by using the 3Ј-RACE protocol. For the first round of PCR, the Ascaris cDNA was amplified by using oligonucleotide N1 and adaptor oligonucleotide R 0 . PCR was performed in 25 cycles comprising each denaturation at 94°C for 1 min, annealing at 55°C for 1 min, and extension at 72°C for 2 min. PCR mixtures were diluted 20-fold and reamplified by using the N2 and R 1 nested oligonucleotides. The prominent PCR products were separated by electrophoresis on 2% agarose gels, recovered by using the QIAEX II gel extraction kit (Qiagen), and cloned into the pGEM-T Easy vector. Fifteen clones containing the amplified 3Ј cDNA fragment were sequenced. The 5Ј end fragment of ACI cDNA was obtained by 5Ј-RACE by using the Smart RACE cDNA amplification kit (BD Biosciences Clontech). Two nested oligonucleotides were designed on the basis of the sequence of the 3Ј cDNA end: gene-specific primer 1 (5Ј-CGATTAGAGTAAATCCCAGCAGCAACC-3Ј, corresponding to nucleotides 290-316 of the full-length ACI cDNA) and gene-specific primer 2 (5Ј-GCAAATCTTTTCATGT-GCCC-3Ј, nucleotides 264-283). After synthesis of the second cDNA strand and ligation of the adaptor oligonucleotide, ''seminested'' PCR was performed with the adaptor primer mix and gene-specific primers 1 and 2 in the first and second rounds of PCR, respectively. The PCR products were analyzed and cloned as described above. Twenty clones containing the amplified 5Ј cDNA fragment were sequenced to generate a consensus sequence.
Heterologous Expression and Purification of Recombinant ACI. The C terminus of the reported ACI sequence (-LPWGL 65 ) was substituted for the C-terminal residues as determined in this study (-GCCWDLL 67 ) by using oligonucleotides designed considering optimal E. coli codon usage. After PCR amplification, the new aci gene was cloned into the pBAT-4-OmpA and pET-32a vectors for expression in E. coli. The enterokinase recognition site of the pET-32a vector was replaced by a TEV protease site to improve the cleavage efficiency of the fusion protein. Recombinant ACI was expressed and purified by using the pBAT-4-OmpA and pET-32a systems as described above. After the purification of the thioredoxin-His 6 -ACI fusion protein, eluted from the Ni 2ϩ -affinity column with 450 mM imidazole, the purified fractions were pooled and dialyzed in cellulose membranes (cutoff 1,000 Da; Membrane Filtration Products) against 50 mM Tris⅐HCl, 0.5 mM EDTA (pH 7.5), further containing 0.5 mM oxidized glutathione and 3 mM reduced glutathione. TEV protease was added during dialysis at an enzyme:substrate ratio of 1:150 (wt/wt) for 24 h at room temperature. Recombinant ACI was finally purified to homogeneity by RP-HPLC as detailed above for the inhibitor with the incorrect sequence. Purity and molecular mass of the inhibitor were assessed, respectively, by SDS/PAGE and MALDI-TOF MS.
Circular Dichroism and NMR Spectroscopy. Samples for far-UV circular dichroism (CD) spectroscopy were prepared by dissolving natural and recombinant ACI at a final protein concentration of 0.5 mg/mL in 20 mM sodium phosphate (pH 8.0). CD analyses were carried out in a Jasco J-715 spectrometer at 25°C by using a cell with 2-mm path length. Denaturation and reduction studies were accomplished by incubating recombinant ACI for 24 h in the same phosphate buffer, which was supplemented with one of the following reagents: 8 M urea, 6-8 M guanidine hydrochloride (GdnHCl), and 10 mM DTT, or in 50 mM Tris⅐HCl (pH 8.5), containing both 8 M GdnHCl and 0.25 mM ␤-mercaptoethanol. For one-dimensional NMR spectroscopy experiments, lyophilized protein powders of natural and recombinant ACI were resuspended to a final protein concentration of 1 mg/mL in 20 mM sodium phosphate (pH 7.0), prepared at a H 2 O:D 2 O volume ratio of 9:1 (99.9% D 2 O). NMR spectra were acquired at different temperatures (25-90°C) in a Bruker AVANCE 600-MHz spectrometer by using solvent-suppression WATERGATE techniques. A two-dimensional NOESY spectrum of recombinant ACI (8 mg/mL) was recorded at 25°C with the mixing times set to 200 ms. The NMR spectra were processed and analyzed by using the TopSpinv2.0 software packages from Bruker Biospin.
MCP Inhibitory Activity. The inhibitory activity of natural ACI and of the recombinant forms comprising the reported sequence and the one determined in the present study was tested by measuring inhibition of the hydrolysis of the chromogenic substrate N-(4-methoxyphenylazoformyl)-Phe-OH by A-type MCPs and N-(4-methoxyphenylazoformyl)-Arg-OH by B-type MCPs at 350 nm in a Cary 400 UV-visible spectrophotometer (Varian). All inhibitory assays were performed in 50 mM Tris⅐HCl, 100 mM NaCl (pH 7.5) containing 100 M substrate. Inhibition constants (K i ) for the complexes of ACI with the MCPs assayed were determined by using presteady-state kinetics as described for tight binding inhibitors (10) . Titration experiments revealed that recombinant ACI is fully functional (specific activity Ͼ90% of the theoretical values). The concentration of ACI used in the assays was determined based on A 280 and a calculated extinction coefficient of E 0.1% ϭ 1.5. TAFI was activated to generate TAFIa immediately before use by incubation of the zymogen (2.2 M) with thrombin (160 nM) and thrombomodulin (200 nM) in 20 mM Tris⅐HCl, 150 mM NaCl (pH 7.5), for 40 min at 23°C. The inhibitory activity of ACI toward CPN was tested by measuring its effect on the hydrolysis of the chromogenic substrate N-(3-[2-Furyl]-acryloyl)-Ala-Lys. The assay was performed in 50 mM Tris⅐HCl (pH 7.5), containing 100 mM NaCl and 0.35 mM substrate at 37°C and 340 nm.
Western Blotting of Natural ACI. Mouse polyclonal antibodies anti-ACI were raised at the Servei de Producció d'Anticossos (Universitat Autònoma de Barcelona, Bellaterra, Spain). Three 8-week-old BALB/c mice were immunized by i.p. injection of 40 g of recombinant ACI as immunogen. Freund's complete adjuvant was used only for the first immunization, and incomplete adjuvant was used in other immunizations. Blood samples were collected from animals before the first injection and after four immunizations. The immune response was monitored by ELISA, and antibody titers were determined as the inverse of the dilution that gave OD 450 values corresponding to 50% of maximal signal. Total serum was collected and stored at Ϫ20°C until use. IgGs were purified from serum by using a 1-mL HiTrap protein A HP column (GE Healthcare) following the manufacturer's guidelines. Body wall, intestine, testis and vas deferens (male), seminal vesicle (male), ovary and oviduct (female), and uterus (female) were excised from adult Ascaris worms. Tissue samples were washed three times in PBS and homogenized in 50 mM Tris⅐HCl, 150 mM NaCl (pH 7.5), by using a Polytron. Homogenates were centrifuged at 35,000 ϫ g for 30 min at 4°C, and the soluble fraction was analyzed by 15% SDS/PAGE. Gels were stained with Coomassie blue or transferred electrophoretically to polyvinylidene fluoride membranes (Millipore). The membranes were blocked with 5% nonfat milk in Tris-buffered saline (TBS) containing 0.1% Tween 20 for 1 h at room temperature and subsequently incubated overnight at 4°C with polyclonal anti-ACI antibodies at 1:500 dilution. After washing in 0.1% Tween/TBS, the membrane was incubated for 2 h at room temperature with a 1:3,000 dilution of goat anti-mouse IgG peroxidase-conjugated secondary antibody (Pierce). Immunolabeling was detected by using Immobilon Western chemiluminescent horseradish peroxidase substrate (Millipore) and visualized on a Versadoc imaging system (Bio-Rad).
Immunohistochemistry of Natural ACI. Adult male and female Ascaris worms were fixed in 4% paraformaldehyde for 10 min at room temperature, injected with the same fixative, cut in 2-cm pieces, and then fixed for another 24 h. Segments from various regions were embedded in paraffin and cut in transverse sections of 5-m thickness. The sections were deparaffinized with xylene and hydrated through descending graded series of ethanol. The slides were then treated with 2% hydrogen peroxide in 70% methanol and blocked for 1 h in PBS containing 5% FBS and 0.2% Triton X-100, followed by treatment with an avidin/biotin blocking kit (Vector Laboratories). Sections were subsequently incubated overnight at 4°C with anti-ACI antibody diluted at 1:50 in the same blocking solution. Mouse serum obtained before immunization was used as negative control. After the immunological reaction, sections were washed in PBS containing 0.2% Triton X-100 and incubated with biotinylated horse antimouse IgG (Vector Laboratories) diluted at 1:500 for 1 h. The washed slides were incubated in avidin-biotin-peroxidase complex reagent of the Vectastain Elite ABC kit (Vector Laboratories) for 30 min, washed, and incubated for 10 min in 3.3Ј-diaminobenzidine tetrahydrochloride (DABϩ; Dako). Sections were then washed in distilled water, counterstained with Harris hematoxylin (Sigma), dehydrated in ethanol, and cleared in xylene. Coverslips were applied over DPX mountant (Sigma). Each section was visualized in a Nikon Eclipse 90i microscope, and images were taken with a Nikon digital camera DXM 1200F coupled to computerized image processing software (ACT-1 version 2.63).
Crystallization of the Complex. The ACI-hCPA1 complex was prepared by incubating equimolar quantities of inhibitor and protease for 1 h at room temperature. The complete inhibition of the carboxypeptidase was checked by a continuous spectrophotometric assay with the chromogenic substrate N-(4-methoxyphenylazoformyl)-Phe-OH. The complex was purified by a HiLoad Superdex 75 26/60 column (GE Healthcare) equilibrated with 50 mM Tris⅐HCl, 250 mM NaCl (pH 7.5). The complex was buffer-exchanged to 10 mM Tris⅐HCl, 50 mM NaCl (pH 7.5) and concentrated to 16.5 mg/mL by using an Amicon Centricon (10-kDa cutoff, Millipore). The purity and integrity of the complex were assessed by SDS/PAGE and MALDI-TOF MS (data not shown). Crystallization assays were performed following the sitting-drop vapor diffusion method. Reservoir solutions were prepared by a Tecan robot, and 200-nL crystallization drops were dispensed on 96-ϫ 3-well CrystalQuick plates (Greiner) by a Cartesian nanodrop robot (Genomic Solutions) at the joint IBMB-CSIC/IRB/Barcelona Science Park HighThroughput Crystallography Platform (PAC). Best crystals appeared after 2-3 weeks in a Bruker steady-temperature crystal farm at 20°C with 0.2 M zinc acetate dihydrate, 0.1 M sodium cacodylate, 9% PEG 8000 (pH 6.5) as reservoir solution. These conditions were successfully scaled up to the microliter range with Cryschem crystallization dishes (Hampton Research) by using drops containing 3 L of protein solution (16.5 mg/mL) and 1 L of reservoir solution. Crystals were cryoprotected through stepwise replacement of the mother liquor with 0.2 M zinc acetate, 0.1 M sodium cacodylate, 35% PEG 8000 (pH 6.5). A complete diffraction dataset was collected at 100 K from a single N 2 flash-cryocooled (Oxford Cryosystems) crystal on an ADSC Q315R CCD detector at beam line ID23-1 of the European Synchrotron Radiation Facility (ESRF; Grenoble, France) within the Block Allocation Group ''BAG Barcelona.'' Crystals were orthorhombic and harbored one complex per asymmetric unit. Diffraction data were integrated, scaled, merged, and reduced with programs XDS (11) and SCALA within the CCP4 suite (12) (see Table S2 ). rigid-body refinement. This solution gave a correlation coefficient in structure factor amplitudes of 56.3% and a crystallographic R factor of 39.4% (for definitions, see Table S2 and ref. 13 ). An electron density map based on calculations with phases derived from the correctly positioned and oriented model revealed extra density for the inhibitor. Subsequently, manual model building on a Silicon Graphics workstation with program TURBO-Frodo alternated with crystallographic refinement with REFMAC5 within the CCP4 suite until completion of the model (see Table S2 ). This model contained the residues of the protease moiety (molecule A) from Ser-2 to Pro-308 and the catalytic zinc ion and the inhibitor residues from Val-3 to Leu-67 (molecule B). All residues lie in allowed regions of a Ramachandran plot according to ref. 14 except Ser-199 (⌽ ϭ 145°; ⌿ ϭ Ϫ12°), as usual in funnelin structures. In addition, a further nine zinc ions, six acetate molecules, and four cacodylate molecules (attributed to the crystallization conditions) were identified in the electron density maps, as well as 564 solvent molecules (see Table S2 ).
Miscellaneous. Nucleotide and amino acid similarity searches were carried out with BLAST (http://blast.ncbi.nlm.nih.gov/ Blast.cgi). Fig. 3 was prepared with programs SETOR (15) and TURBO-Frodo. Structural similarity searches were performed with DALI (http://ekhidna.biocenter.helsinki.fi/daliserver), SSM within SCOP (www.ebi.ac.uk/msd-srv/ssm), VAST (www. ncbi.nlm.nih.gov/structure/vast/vastsearch.html), and the CA-THEDRAL server within CATH (www.cathdb.info/cgi-bin/ cath). None of these searches revealed substantial structural similarity beyond generic strand-turn-strand-helix-containing motifs to any protein of known structure. Surfaces and intramolecular close contacts (Ͻ4 Å) were calculated by using a sphere radius of 1.4 Å with program CNS (16) . The value of the complex interface was estimated taking the half of the difference between the sum of the individual molecular surfaces and the total complex surface.
Structure of Human Carboxypeptidase A1. The structure of hCPA1 consists of a central eight-stranded ␤-sheet (strands ␤1-␤8), which vertically spans the molecule top to bottom, accumulating a vertical twist. Three helices (␣5, ␣7, ␣8) and the active-site cleft nestle into the concave face of the sheet, and six helices (␣1-␣4, ␣6, and ␣9) plus the N and C termini of the molecule lie on the convex side of the sheet (Fig. 3A) . The access to the active site is like a funnel, whose rim is shaped by a series of irregular loop segments required for interactions of such A/B-type protease moieties with pro-domains and cognate protein inhibitors (17, 18) . These segments comprise the loop connecting strand ␤3 with helix ␣2 (L␤3␣2), L␤5␤6, L␣7␣8, and L␤8␣9, and the initial and central parts of the 52-residue segment connecting ␣4 and ␣5 (L␣4␣5). This long segment features a compact subdomain, cross-linked by a disulfide bond (Cys-138-Cys-161), and it closes the front and the bottom of the active site and the specificity pocket, thus contributing to the characteristic cul-de-sac of funnelin exopeptidases.
The catalytic zinc ion of hCPA1 resides at the bottom of the funnel-like cleft and is coordinated by His-69 N␦1 (2.08 Å apart) and, asymmetrically, by Glu-72 O2 (1.97 Å) and O2 (2.85 Å) (Fig. S7B) . These 2 residues are embedded in a consensus motif sequence, HXXE (amino acid one-letter code; X for any residue), characteristic of A/B-and N/E-type MCPs (17, 19) . The third zinc ligand is His-196 N␦1 (2.10 Å). As found in related enzymes (17, 20, 21) , the protein residues engaged in substrate binding are Tyr-198, Ser-199, Tyr-248, and Phe-279, which form substrate-binding subsite S 1 (for subsite nomenclature, see ref.
22); Arg-71, Glu-163, Thr-164, and Arg-127 contributing to S 2 . In addition, Arg-71, Tyr-198, and Phe-279 also contribute to S 3 . The commonly accepted mechanism foresees that a zinc-bound solvent molecule, which is further polarized by the general base/acid Glu-270, attacks the scissile bond carbonyl group (for a detailed review, see ref. 17 and references therein). Typical A-type MCP specificity toward aliphatic side chains in substrates is caused by a rather small hydrophobic S 1Ј pocket. In hCPA1, it is shaped by the side chains of Asn-144, Arg-145, Ser-194, Met-203, Ile-243, Ile-247, Ala-250, Ser-253, Thr-254, Thr-268 (present in alternate conformation for its side chain), Tyr-248, and Ile-255. The terminal carboxylate group of a substrate, when it is trapped for scission, is fixed by Asn-144, Arg-145, and Tyr-248, whereas the scissile carbonyl group is near Glu-270, Arg-127, and the catalytic zinc (Fig. S7B) . . Unfertilized eggs may be ingested but are not infective. Fertile eggs embryonate and become infective after 18 days to several weeks (point 3), depending on the environmental conditions (optimum: moist, warm, shaded soil). After infective eggs are swallowed (point 4), larvae hatch (point 5), invade the intestinal mucosa, and are carried via the blood system to the lungs (point 6). The larvae mature further in the lungs (10 -14 days), penetrate the alveolar walls, ascend the bronchial tree to the throat, and are then (re)swallowed (point 7). Upon reaching the small intestine, they develop into adult worms (point 1) that reach a maximal length of 35 cm. Between 2 and 3 months are required from ingestion of the infective eggs to oviposition by the adult female. Adult worms can live 1-2 years. Figure adapted from DPDx, the CDC parasitology website (www.dpd.cdc.gov/dpdx/default.htm).
Fig. S2
. RP-HPLC analysis of recombinant ACI comprising the reported sequence (4). ACI expressed in E. coli by using either the pBAT-4-OmpA or the pET-32a vectors was analyzed by RP-HPLC on a Vydac C4 column by using a linear gradient from 10 to 50% acetonitrile with 0.1% trifluoroacetic acid for 50 min. Two forms of the inhibitor, named A and B, were detected eluting, respectively, after 35 and 36 min of chromatography. Table S2 . Crystallographic data
